ECOST

ECOST

Effectiveness and Cost Of ICD Follow-up Schedule With Telecardiology

Study Design

  • Randomized, interventional, multicenter study
  • To compare the safety of continuous Home Monitoring versus conventional ambulatory follow-up of ICDs.
  • 433 patients at 43 centers in France

Key Result 1

Remote follow-up with BIOTRONIK Home Monitoring® is as safe as conventional ambulatory follow-up.

圖片
Proportion of Patients

Key Result 2

Continuous monitoring with BIOTRONIK Home Monitoring® reduced the rate of patients who experienced inappropriate shocks significantly by 52%. 72% fewer hospitalizations due to inappropriate shocks.

圖片
Inappropriate shocks

Key Result 3

BIOTRONIK Home Monitoring® reduced the number of charged shocks by 76%. Reducing shocks saved 7.9 months of battery longevity.

圖片
Number of Capacitors Charges

Clinical relevance

  • The ECOST study shows that BIOTRONIK Home Monitoring of ICDs as a safe alternative to in-office follow-ups. It positively impact on patient outcome , specially when it comes to reducing the risk of inappropriate shocks – a very unpleasant experience.
  • The value of BIOTRONIK Home Monitoring for continuous remote monitoring, through its daily transmissions, is essential for clinics to better manage their patients health condition.
Reference no.
  • NCT00989417
1° Endpoints
  • The proportion of patients who experienced ≥ 1 MAE, including death from any cause, cardiovascular and procedure or device related MAE.
2° Endpoints
  • Appropriate and inappropriate shock deliveries
  • ICD capacitor charges
  • Impact on battery longevity
Clinical Sites
  • 43 centers
Sample Size
  • 433 patients
Inclusion Criteria
  • Indication for single or dual chamber ICD
Main Exclusion Criteria #1
  • NYHA class IV
  • Pregnant woman or woman who plan to become pregnant during the trial
  • Patient whose medical situation is not stable
  • Presence of any disease, other than patient's cardiac disease, associated with reduced likelihood of survival for the duration of the trial, e.g. cancer, uraemia (urea > 70mg/dl or creatinine >3mg/dl), liver failure, etc.
  • Age
  • Patient unable to handle Home Monitoring system correctly
  • The patient is not willing and able to comply with the protocol
  • Change of residence expected during study
Main Exclusion Criteria #2
  • Insufficient GSM coverage at patient's home
  • Participation in another clinical study
  • Patient unwilling to sign the consent for participation.
Devices
  • ICDs equipped with BIOTRONIK Home Monitoring
Study FlowchartStudy Flowchart
Follow-Up
  • 27 months follow-up
Study Duration
  • January 2007 – October 2010 (Final data collection date for primary outcome measure)
Principal Investigators
  • Salem S. Kacet, Prof. Dr. , CHRU de Lille – Hospital Cardiologique, France

Download Section


Related Products

Tachycardia Therapy

BIOTRONIK offers an extensive product portfolio in the area of tachycardia therapy.

Tachy Teaser
Monitoring Teaser

Cardiac Remote Monitoring

BIOTRONIK offers Home Monitoring for its complete product portfolio.